Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
View through CrossRef
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal infections in adults, as well as to treat patients infected with Carbapenem‐resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI. However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains. Mechanisms of resistance in most of these strains have been attributed to blaKPC mutations, which lead to amino acid substitutions in β‐lactamase and changes in gene expression. Resistance to CAZ/AVI is also associated with reduced expression and loss of outer membrane proteins or overexpression of efflux pumps. In this review, the prevalence of CAZ/AVI‐resistance bacteria, resistance mechanisms, and selection of detection methods of CAZ/AVI are demonstrated, aiming to provide scientific evidence for the clinical prevention and treatment of CAZ/AVI resistant strains, and provide guidance for the development of new drugs.This article is categorized under:
Infectious Diseases > Molecular and Cellular Physiology
Title: Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
Description:
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.
S.
Food and Drug Administration, the European Union, and the National Regulatory Administration in China.
CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal infections in adults, as well as to treat patients infected with Carbapenem‐resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI.
However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains.
Mechanisms of resistance in most of these strains have been attributed to blaKPC mutations, which lead to amino acid substitutions in β‐lactamase and changes in gene expression.
Resistance to CAZ/AVI is also associated with reduced expression and loss of outer membrane proteins or overexpression of efflux pumps.
In this review, the prevalence of CAZ/AVI‐resistance bacteria, resistance mechanisms, and selection of detection methods of CAZ/AVI are demonstrated, aiming to provide scientific evidence for the clinical prevention and treatment of CAZ/AVI resistant strains, and provide guidance for the development of new drugs.
This article is categorized under:
Infectious Diseases > Molecular and Cellular Physiology.
Related Results
P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
P25 Ceftazidime/avibactam and cefiderocol use in adults in a South London Trust
Abstract
Background
NHS England now subsidizes pharmaceutical firms to invest in new antibiotic development. Currently, this app...
Mutation-driven evolution of
Pseudomonas aeruginosa
in the presence of either ceftazidime or ceftazidime/avibactam
Mutation-driven evolution of
Pseudomonas aeruginosa
in the presence of either ceftazidime or ceftazidime/avibactam
ABSTRACT
Ceftazidime/avibactam is a combination of beta-lactam/beta-lactamases inhibitor, which use is restricted to some clinical cases includin...
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Abstract
Background
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain sus...
Phenotypic and Molecular Characterization of the blaTEM Gene in Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae
Phenotypic and Molecular Characterization of the blaTEM Gene in Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae
Abstract
Introduction
There has been a notable rise in antibiotic resistance among enterobacteria. This issue is primarily attributed to the emergence of extended-spectrum beta-lac...
Effectiveness of ceftazidime/avibactam as a continuous infusion in critically ill patients with OXA-48-producing Klebsiella pneumoniae infection
Effectiveness of ceftazidime/avibactam as a continuous infusion in critically ill patients with OXA-48-producing Klebsiella pneumoniae infection
Introduction. Ceftazidime/avibactam, a novel beta-lactam antibiotic, demonstrates time-dependent bacterial killing; thus, new reports advocate its administration as a continuous in...
Antimicrobial susceptibility pattern of ceftazidime-avibactam against Eschericia Coli.
Antimicrobial susceptibility pattern of ceftazidime-avibactam against Eschericia Coli.
Objectives: To identify the susceptibility of Ceftazidime-avibactam against Escherichia coli and their frequency in different clinical specimens. To correlate the susceptibility pa...
KPC-2 allelic variants in
Klebsiella pneumoniae
isolates resistant to ceftazidime-avibactam from Argentina:
bla
KPC-80
,
bla
KPC-81
,
bla
KPC-2 allelic variants in
Klebsiella pneumoniae
isolates resistant to ceftazidime-avibactam from Argentina:
bla
KPC-80
,
bla
KPC-81
,
bla
ABSTRACT
Ceftazidime-avibactam (CZA) therapy has significantly improved survival rates for patients infected by carbapenem-resist...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...